Journal Mobile Options
Table of Contents
Vol. 219, No. 4, 2009
Issue release date: November 2009

Homoeopathic versus Conventional Therapy for Atopic Eczema in Children: Medical and Economic Results

Witt C.M. · Brinkhaus B. · Pach D. · Reinhold T. · Wruck K. · Roll S. · Jäckel T. · Staab D. · Wegscheider K. · Willich S.N.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: One of five children visiting a homoeopathic physician is suffering from atopic eczema. Objective: To examine the effectiveness, safety and costs of homoeopathic versus conventional treatment in usual care. Methods: In a prospective multicentre comparative observational non-randomised study, 135 children (homoeopathy n = 48 vs. conventional n = 87) with mild to moderate atopic eczema were included. The primary outcome was the SCORAD (Scoring Atopic Dermatitis) at 6 months. Further outcomes at 6 and 12 months also included quality of life of parents and children, use of conventional medicine, treatment safety and disease-related costs. Results: The adjusted SCORAD showed no significant differences between the groups at both 6 months (homoeopathy 22.49 ± 3.02 [mean ± SE] vs. conventional 18.20 ± 2.31, p = 0.290) and 12 months (17.41 ± 3.01 vs. 17.29 ± 2.31, p = 0.974). Adjusted costs were higher in the homoeopathic than in the conventional group: for the first 6 months EUR 935.02 vs. EUR 514.44, p = 0.026, and for 12 months EUR 1,524.23 vs. EUR 721.21, p = 0.001. Quality of life was not significantly different between both groups. Conclusion: Taking patient preferences into account, homoeopathic treatment was not superior to conventional treatment for children with mild to moderate atopic eczema.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Szucs T: Sozioökonomische Aspekte der Neurodermitis in Deutschland; in Riedl-Seifert R (ed): Expert Report zu Bufexamac. München, Zuckschwerdt, 1995, pp 49–66.
  2. Augustin M, Zschocke I: Lebensqualität und Ökonomie bei allergischen Hauterkrankungen. Allergologie 2001;24:433–442.

    External Resources

  3. Gieler U, Hohmann M, Niemeyer V: Cost evaluation in atopic eczema. J Dermatol Treat 1999;10(suppl 1):15–21.
  4. Buys LM: Treatment options for atopic dermatitis. Am Fam Physician 2007;75:523–528.
  5. Williams H, Robertson C, Stewart A, et al: Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999;103:125–138.
  6. Werner S, Buser K, Kapp A, Werfel T: The incidence of atopic dermatitis in school entrants is associated with individual life-style factors but not with local environmental factors in Hannover, Germany. Br J Dermatol 2002;147:95–104.
  7. Brown S, Reynolds NJ: Atopic and non-atopic eczema. BMJ 2006;332:584–588.
  8. Keil T, Witt CM, Roll S, Vance W, Weber K, Wegscheider K, Willich SN: Homoeopathic versus conventional treatment of children with eczema: a comparative cohort study. Complement Ther Med 2008;16:15–21.
  9. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB: Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003;49:1088–1095.
  10. Flohr C, Johansson SG, Wahlgren CF, Williams H: How atopic is atopic dermatitis? J Allergy Clin Immunol 2004;114:150–158.
  11. Bieber T: Atopic dermatitis. N Engl J Med 2008;358:1483–1494.
  12. Goujon C, Jean-Decoster C, Dahel K, Bottigioli D, Lahbari F, Nicolas JF, Schmitt AM: Tolerance of oat-based topical products in cereal-sensitized adults with atopic dermatitis. Dermatology 2009;218:327–333.
  13. King RM, Wilson GV: Use of a diary technique to investigate psychosomatic relations in atopic dermatitis. J Psychosom Res 1991;35:697–706.
  14. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Leitlinien der Deutschen Dermatologischen Gesellschaft (DDG) und des Berufsverbandes Deutscher Dermatologen (BVDD): Atopische Dermatitis. 2002. www.awmf-leitlinien.de.
  15. Werfel T, Claes C, Kulp W, Greiner W, Graf von der Schulenburg J: HTA-Bericht: Therapie der Neurodermitis. Köln, DIMDI, 2006.
  16. Jensen P: Alternative medicine and chronic skin disease: use of alternative treatments among patients with atopic eczema and psoriasis. Tidsskr Nor Laegeforen 1990;110:2869–2872.
  17. Schäfer T, Riehle A, Wichmann HE, Ring J: Alternative medicine in allergies – prevalence, patterns of use, and costs. Allergy 2002;57:694–700.
  18. Magin PJ, Adams J, Heading GS, Pond DC, Smith W: Complementary and alternative medicine therapies in acne, psoriasis, and atopic eczema: results of a qualitative study of patients’ experiences and perceptions. J Altern Complement Med 2006;12:451–457.
  19. Becker-Witt C, Lüdtke R, Weisshuhn TE, Willich SN: Diagnoses and treatment in homeopathic medical practice. Forsch Komplementärmed Klass Naturheilkd 2004;11:98–103.
  20. Jonas W, Jacobs J: Healing with Homeopathy. New York, Warner, 1996.
  21. Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV, Jonas WB: Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet 1997;350:834–843.
  22. Witt CM, Lüdtke R, Baur R, Willich SN: Homeopathic medical practice: long-term results of a cohort study with 3,981 patients. BMC Public Health 2005;5:115.
  23. Williams HC, Burney PG, Strachan D, Hay RJ: The UK Working Party’s diagnostic criteria for atopic dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 1994;131:397–405.
  24. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, Bingham EA, Finlay AY, Pembroke AC, Graham-Brown RA: The UK Working Party’s diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994;131:383–396.
  25. Wolkerstorfer A, de Waard van der Spek FB, Glazenburg EJ, Mulder PG, Oranje AP: Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol 1999;79:356–359.
  26. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23–31.
  27. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10–19.
  28. Schmitt J, Langan S, Williams HC: What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007;120:1389–1398.
  29. von Rüden U, Staab D, Kehrt R, Wahn U: Entwicklung und Validierung eines krankheitsspezifischen Fragebogens zur Erfassung der Lebensqualität von Eltern neurodermitiskranker Kinder. Z Gesundheitswiss 1999;7:335–350.
  30. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, Scheewe S, Scheidt R, Schmid-Ott G, Schnopp C: Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006;332:933–938.
  31. Lewis-Jones MS, Finlay AY: The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995;132:942–949.
  32. Schmitt J, Meurer M, Schwanebeck U, Grahlert X, Schakel K: Treatment following an evidence-based algorithm versus individualised symptom-oriented treatment for atopic eczema: a randomised controlled trial. Dermatology 2008;217:299–308.
  33. Witt C, Keil T, Selim D, Roll S, Vance W, Wegscheider K, Willich SN: Outcome and costs of homoeopathic and conventional treatment strategies: a comparative cohort study in patients with chronic disorders. Complement Ther Med 2005;13:79–86.
  34. Ehlken B, Mohrenschlager M, Kugland B, Berger K, Quednau K, Ring J: Cost-of-illness study in patients suffering from atopic eczema in Germany. Hautarzt 2005;56:1144–1151.
  35. Su JC, Kemp AS, Varigos GA, Nolan TM: Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997;76:159–162.
  36. Kemp AS: Atopic eczema: its social and financial costs. J Paediatr Child Health 1999;35:229–231.
  37. Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, Lebwohl M, Stevens SR, Whitaker-Worth DL, Cheng JW: Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002;46:361–370.
  38. Herd RM, Tidman MJ, Prescott RJ, Hunter JA: The cost of atopic eczema. Br J Dermatol 1996;135:20–23.
  39. Emerson RM, Williams HC, Allen BR: What is the cost of atopic dermatitis in preschool children? Br J Dermatol 2001;144:514–522.
  40. Barbeau M, Bpharm HL: Burden of atopic dermatitis in Canada. Int J Dermatol 2006;45:31–36.
  41. Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F: The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002;147:716–724.
  42. Siebenwirth J: A randomized, placebo controlled, double blind study testing the effectiveness of classical homeopathic therapy of atopic dermitis (AD); in Walach H, Schneider R (eds): Future Directions and Current Issues of Research in Homeopathy. Freiburg, Chez, 2002, pp 79–90.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50